Organic Group Revenue Growth: 3% increase. EBITDA Pre: Increased by 6% to EUR 1.535 billion. Net Sales: Increased by 3.1% to EUR 5.208 billion. EPS Pre: Increased by 2.9% to EUR 2.12 per share. Operating Cash Flow: Decreased by EUR 556 million. Net Financial Debt: Decreased slightly compared to end of December last year. Healthcare Organic Sales Growth: 3.4% increase. Life Science Organic Sales Growth: 2.5% increase. Electronics Organic Sales Growth: 0.6% increase. Process Solutions Growth: 11% increase. EBIT: Increased by 8% year on year. Effective Tax Rate: 22.8%. Reported EPS: EUR 1.69, a 5.6% increase year on year. Semiconductor Materials Growth: 2% increase. Equity Ratio: Strengthened from 58% to 61%.

Warning! GuruFocus has detected 3 Warning Sign with MKGAF.

Release Date: May 15, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Merck KGaA (MKGAF) achieved profitable growth across all three business sectors in Q1 2025, with group revenues increasing by 3% organically and EBITDA pre rising by 6%. Process Solutions showed remarkable progress, crossing into double-digit growth with an 11% increase in Q1, driven by strong order intake and a book-to-bill ratio comfortably above 1. Healthcare delivered organic sales growth of 3.4%, supported by strong performance in the CM&E portfolio and solid growth of Erbitux and Mavenclad. Electronics experienced positive organic sales development, particularly in Semiconductor Materials, which contributed to a 2% growth in the Semiconductor Solutions business. Merck KGaA (MKGAF) has taken proactive measures to mitigate potential impacts from tariffs and currency fluctuations, demonstrating adaptability in a challenging macroeconomic environment.

Negative Points

Operating cash flow decreased by EUR556 million, primarily due to an increase in receivables and inventories, higher bonus payments, and higher tax payments. Science & Lab Solutions (SLS) faced a decline in sales by 2.5% organically, impacted by US policy changes affecting academic and government lab spending and a cautious pharma research spending environment. Life Science Services saw a 6.2% organic decline in sales, mainly driven by CDMO activities affected by funding constraints and unfavorable project phasing. The Electronics sector's DS&S business experienced a low double-digit percentage decline due to customer projects being pushed out further. Merck KGaA (MKGAF) adjusted its 2025 guidance corridors due to currency movements, particularly a weak US dollar, and potential tariff impacts, reflecting ongoing macroeconomic volatility.

Story Continues

Q & A Highlights

Q: Could you discuss the expected performance of the Science & Lab Solutions (SLS) division for Q2 and the rest of the year, considering the impact of NIH funding and R&D budget weaknesses? Also, how do you see the situation in China affecting sales due to the reduced tariff window? A: Jean-Charles Wirth, Designated CEO, Life Science, explained that while facing dynamic macroeconomic challenges, SLS is expected to perform better in the second half of the year compared to the first. The company aims to reach its midterm guidance exit rate. Regarding China, the reduced tariff window might lead to increased sales in Q2, but the longer-term impact of NIH budget cuts for 2026 remains uncertain.

Q: What gives you confidence that the strong order intake in Process Solutions isn't due to pre-ordering, especially given the spike in pharma imports in the US? A: Matthias Heinzel, CEO, Life Science, stated that they closely monitor business trends and customer behavior, confirming no material pre-ordering. The strong order intake is broad-based across regions and customer segments, indicating genuine underlying demand.

Q: Can you provide insights into the SpringWorks Therapeutics acquisition, particularly regarding cost integration, synergies, and one-time deal costs? A: Danny Bar-Zohar, Designated CEO, Healthcare, mentioned that the transaction is expected to be accretive by 2027, with transaction and integration costs of EUR150 million each. Most transaction costs will occur in 2025, while integration costs will spread over 2025 to 2027. The deal aims to unlock potential value in the US and internationally, with no major cost synergies expected.

Q: Could you elaborate on the industry's efforts to reach an acceptable tariff deal with the administration, and how does this affect Merck's strategy? A: Belen Garijo, CEO, explained that Merck is actively contributing to discussions through trade associations to shape a favorable environment in the US. The company has taken mitigation measures to handle potential tariff impacts and does not expect significant short-term effects in 2025.

Q: What are the expectations for Bavencio's performance for the full year, and do you anticipate recovery in the DS&S business? A: Danny Bar-Zohar, Designated CEO, Healthcare, indicated that Bavencio's sales are expected to decline by around 15% this year, with stabilization anticipated in 2026. Kai Beckmann, CEO, Electronics, noted that the DS&S business is recovering from a high base, with strong performance in materials supporting the overall Semiconductor Solutions segment.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments